Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired immune-mediated diseases, which typically involve the striated muscle with a variable involvement of the skin and other organs. Clinically, they are characterized by proximal muscle weakness, elevation of muscle enzymes,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Acosta,Ignacio, Matamala,José Manuel, Jara,Paula, Pino,Francisca, Gallardo,Alejandra, Verdugo,Renato
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2019
Materias:	Dermatomyositis Inclusion Body Myositis Polymyositis
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000300342
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872019000300342
record_format	dspace
spelling	oai:scielo:S0034-988720190003003422019-07-17Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejoAcosta,IgnacioMatamala,José ManuelJara,PaulaPino,FranciscaGallardo,AlejandraVerdugo,Renato Dermatomyositis Inclusion Body Myositis Polymyositis Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired immune-mediated diseases, which typically involve the striated muscle with a variable involvement of the skin and other organs. Clinically, they are characterized by proximal muscle weakness, elevation of muscle enzymes, myopathic changes on electromyography and an abnormal muscle biopsy. The different IIM have been classified according to their distinctive histopathologic features in dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and immune-mediated necrotizing myopathy (IMNM). Several myositis-specific antibodies are associated with the different phenotypes, as well as with different risk of neoplastic disease and systemic complications. The basis for the treatment of DM, PM, and IMNM is immunosuppression. For IBM there are only symptomatic treatments. Steroids, associated or not with other immunosuppressant drugs, are the first line of treatment. Biologic drugs will allow future individualized therapies. The 10-year survival of DM, PM and IMNM is 62 to 90%. The leading causes of death are neoplastic, lung and cardiac complications. IBM does not impair survival, although it affects the quality of life.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.147 n.3 20192019-03-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000300342es10.4067/S0034-98872019000300342
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Dermatomyositis Inclusion Body Myositis Polymyositis
spellingShingle	Dermatomyositis Inclusion Body Myositis Polymyositis Acosta,Ignacio Matamala,José Manuel Jara,Paula Pino,Francisca Gallardo,Alejandra Verdugo,Renato Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo
description	Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of acquired immune-mediated diseases, which typically involve the striated muscle with a variable involvement of the skin and other organs. Clinically, they are characterized by proximal muscle weakness, elevation of muscle enzymes, myopathic changes on electromyography and an abnormal muscle biopsy. The different IIM have been classified according to their distinctive histopathologic features in dermatomyositis (DM), polymyositis (PM), inclusion body myositis (IBM) and immune-mediated necrotizing myopathy (IMNM). Several myositis-specific antibodies are associated with the different phenotypes, as well as with different risk of neoplastic disease and systemic complications. The basis for the treatment of DM, PM, and IMNM is immunosuppression. For IBM there are only symptomatic treatments. Steroids, associated or not with other immunosuppressant drugs, are the first line of treatment. Biologic drugs will allow future individualized therapies. The 10-year survival of DM, PM and IMNM is 62 to 90%. The leading causes of death are neoplastic, lung and cardiac complications. IBM does not impair survival, although it affects the quality of life.
author	Acosta,Ignacio Matamala,José Manuel Jara,Paula Pino,Francisca Gallardo,Alejandra Verdugo,Renato
author_facet	Acosta,Ignacio Matamala,José Manuel Jara,Paula Pino,Francisca Gallardo,Alejandra Verdugo,Renato
author_sort	Acosta,Ignacio
title	Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo
title_short	Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo
title_full	Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo
title_fullStr	Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo
title_full_unstemmed	Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo
title_sort	miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo
publisher	Sociedad Médica de Santiago
publishDate	2019
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872019000300342
work_keys_str_mv	AT acostaignacio miopatiasinflamatoriasidiopaticasunamiradaactualizadaaldiagnosticoyelmanejo AT matamalajosemanuel miopatiasinflamatoriasidiopaticasunamiradaactualizadaaldiagnosticoyelmanejo AT jarapaula miopatiasinflamatoriasidiopaticasunamiradaactualizadaaldiagnosticoyelmanejo AT pinofrancisca miopatiasinflamatoriasidiopaticasunamiradaactualizadaaldiagnosticoyelmanejo AT gallardoalejandra miopatiasinflamatoriasidiopaticasunamiradaactualizadaaldiagnosticoyelmanejo AT verdugorenato miopatiasinflamatoriasidiopaticasunamiradaactualizadaaldiagnosticoyelmanejo
_version_	1718437053382787072

Miopatías inflamatorias idiopáticas: una mirada actualizada al diagnóstico y el manejo

Ejemplares similares